| Nov 1 |
Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston
|
| Oct 23 |
Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024
|
| Oct 17 |
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer
|
| Oct 9 |
Ligand Pharmaceuticals Inc (LGND) Q2 2024 Earnings Call Highlights: Robust Revenue Growth Amid ...
|
| Oct 9 |
LGND: Initiating Coverage – A Prince Among Royalty
|
| Oct 3 |
Ligand started at outperform by Oppenheimer on royalty revenue growth
|
| Sep 25 |
Can Mixed Fundamentals Have A Negative Impact on Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Current Share Price Momentum?
|
| Sep 6 |
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
|
| Sep 6 |
Travere gains on full FDA approval for kidney drug Filspari
|
| Aug 27 |
Insider Sale: President & COO Matthew Korenberg Sells 18,858 Shares of Ligand ...
|
